Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
You may also be interested in...
Sales of the Bristol PD-1 inhibitor dropped 9% year-over-year but the company says approvals in first-line NSCLC are off to a good start. Q2 saw growth for Eliquis and Revlimid despite pandemic impact.
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.
Themis’ CEO on how Merck’s commitment to infectious diseases impressed him, and why regulators may not approve suboptimal COVID-19 vaccines.